#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	17522	16S	1529	1529	100.0	16S.l15.c4.ctg.2	2359	889.7	1	SNP	n	C1184T	0	.	.	1184	1184	C	1448	1448	C	1075	C,T	1072,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	17522	16S	1529	1529	100.0	16S.l15.c4.ctg.2	2359	889.7	0	HET	.	.	.	C260T,G,A	.	260	260	C	524	524	C	939	C,T,G,A	740,193,4,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29408	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4048	904.7	0	.	n	.	0	T695C	SNP	695	695	T	1246	1246	C	1048	C,T,A	1046,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29408	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4048	904.7	0	.	n	.	0	G1337A	SNP	1337	1337	G	1888	1888	A	1212	A,G,T	1208,2,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29408	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4048	904.7	0	.	n	.	0	T1971C	SNP	1971	1971	T	2522	2522	C	1082	C,G,A	1079,2,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29408	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4048	904.7	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3148	3148	T	1005	T	1005	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29408	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4048	904.7	1	SNP	n	A2045G	0	.	.	2045	2045	A	2596	2596	A	1021	A,G,T	1018,2,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	2628	folP	852	852	100.0	folP.l15.c17.ctg.1	2153	152.2	1	SNP	p	R228S	1	.	.	682	684	AGC	1280	1282	AGC	255;257;256	A;G,T;C,G,A	255;256,1;254,1,1	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	6146	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3962	193.4	1	SNP	p	S91F	0	.	.	271	273	TCC	924	926	TCC	231;232;231	T;C;C,A,T	231;232;229,1,1	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	6146	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3962	193.4	1	SNP	p	D95N	0	.	.	283	285	GAC	936	938	GAC	232;233;231	G,C;A;C	231,1;233;231	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	6146	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3962	193.4	1	SNP	p	D95G	0	.	.	283	285	GAC	936	938	GAC	232;233;231	G,C;A;C	231,1;233;231	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_M_01390	mtrR.WHO_M_01390	1	1	27	2206	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1767	155.5	1	SNP	p	G45D	1	.	.	133	135	GAC	677	679	GAC	247;245;246	G;A;C	247;245;246	mtrR.WHO_M_01390:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	1248	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	1503	103.5	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	6118	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3578	212.9	1	SNP	p	D86N	0	.	.	256	258	GAC	886	888	GAC	274;275;273	G;A,C;C,T,G	274;274,1;271,1,1	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	6118	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3578	212.9	1	SNP	p	S87I	0	.	.	259	261	AGT	889	891	AGT	275;277;277	A,G;G;T	274,1;277;277	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	6118	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3578	212.9	1	SNP	p	S87R	0	.	.	259	261	AGT	889	891	AGT	275;277;277	A,G;G;T	274,1;277;277	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	6118	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3578	212.9	1	SNP	p	S87W	0	.	.	259	261	AGT	889	891	AGT	275;277;277	A,G;G;T	274,1;277;277	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	6118	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3578	212.9	1	SNP	p	S88P	0	.	.	262	264	TCC	892	894	TCC	277;278;277	T;C;C	277;278;277	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4974	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3124	198.2	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1791	1793	GGC	264;264;263	G;G;C	264;264;263	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	4686	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2846	204.9	1	SNP	p	A311V	0	.	.	931	933	GCA	1538	1540	GCA	315;316;319	G,T;C;A,G	314,1;316;318,1	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4686	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2846	204.9	1	SNP	p	I312M	0	.	.	934	936	ATC	1541	1543	ATC	320;316;314	A;T;C,T	320;316;313,1	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4686	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2846	204.9	1	SNP	p	V316P	0	.	.	946	948	GTG	1553	1555	GTG	312;314;311	G;T,A;G	312;313,1;311	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4686	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2846	204.9	1	SNP	p	V316T	0	.	.	946	948	GTG	1553	1555	GTG	312;314;311	G;T,A;G	312;313,1;311	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4686	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2846	204.9	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2057	2059	ACC	265;263;261	A,G,T;C;C	263,1,1;263;261	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4686	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2846	204.9	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2111	2113	GCG	258;256;254	G,C;C;G,C	257,1;256;253,1	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4686	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2846	204.9	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2111	2113	GCG	258;256;254	G,C;C;G,C	257,1;256;253,1	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4686	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2846	204.9	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2234	2236	GGC	227;229;228	G;G;C	227;229;228	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4686	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2846	204.9	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2243	2245	GGC	230;230;231	G;G,A;C	230;229,1;231	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4686	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2846	204.9	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2261	2263	CCG	243;243;247	C,G;C;G,T	242,1;243;246,1	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	6466	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3699	217.9	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	3138	porA	1146	1146	99.83	porA.l6.c30.ctg.1	2361	165.7	0	.	p	.	0	M83fs	FSHIFT	247	247	A	857	857	C	243	C,A	242,1	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	338	porB1a	984	292	90.54	porB1a.l15.c30.ctg.1	932	26.9	0	.	p	.	0	H217N	NONSYN	649	651	CAT	665	667	AAT	3;3;3	A;A;T	3;3;3	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	338	porB1a	984	292	90.54	porB1a.l15.c30.ctg.1	932	26.9	0	.	p	.	0	D218N	NONSYN	652	654	GAT	668	670	AAT	3;3;3	A;A;T	3;3;3	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	338	porB1a	984	292	90.54	porB1a.l15.c30.ctg.1	932	26.9	0	.	p	.	0	A222V	NONSYN	664	666	GCT	680	682	GTT	3;3;3	G;T;T	3;3;3	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	338	porB1a	984	292	90.54	porB1a.l15.c30.ctg.1	932	26.9	0	.	p	.	0	V226A	NONSYN	676	678	GTA	692	694	GCA	4;4;4	G;C;A	4;4;4	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	338	porB1a	984	292	90.54	porB1a.l15.c30.ctg.1	932	26.9	0	.	p	.	0	.	MULTIPLE	700	702	ACT	715	717	GTA	6;6;6	G;T;A	6;6;6	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	338	porB1a	984	292	90.54	porB1a.l15.c30.ctg.1	932	26.9	0	.	p	.	0	N237fs	FSHIFT	709	709	A	724	724	A	6	A	6	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	3252	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1725	234.4	0	.	p	.	0	G38E	NONSYN	112	114	GGA	620	622	GAA	311;307;308	G,C;A;A	310,1;307;308	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	3252	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1725	234.4	0	.	p	.	0	E48G	NONSYN	142	144	GAA	650	652	GGA	299;299;300	G;G;A	299;299;300	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	3252	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1725	234.4	0	.	p	.	0	T87A	NONSYN	259	261	ACT	767	769	GCT	289;290;290	G;C,A;T	289;288,2;290	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	3252	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1725	234.4	0	.	p	.	0	T89S	NONSYN	265	267	ACC	773	775	AGC	284;283;283	A;G;C,A	284;283;282,1	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	3252	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1725	234.4	0	.	p	.	0	.	MULTIPLE	358	359	AA	865	866	CG	241;241	C;G	241;241	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	3252	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1725	234.4	0	.	p	.	0	.	MULTIPLE	361	362	GA	868	870	CAG	241;241;235	C;A;G	241;241;235	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	3252	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1725	234.4	0	.	p	.	0	N122K	NONSYN	364	366	AAC	872	874	AAA	231;236;236	A;A,T;A,C	231;235,1;235,1	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	3252	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1725	234.4	0	.	p	.	0	K143E	NONSYN	427	429	AAA	935	937	GAA	260;259;256	G,A;A,G;A	258,1;257,1;255	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	3252	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1725	234.4	0	.	p	.	0	V151A	NONSYN	451	453	GTA	959	961	GCA	261;261;261	G;C;A	261;261;261	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	3252	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1725	234.4	0	.	p	.	0	N212D	NONSYN	634	636	AAT	1142	1144	GAT	294;294;295	G;A;T	294;294;295	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	3252	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1725	234.4	0	.	p	.	0	D213G	NONSYN	637	639	GAT	1145	1147	GGT	297;291;286	G,C,T;G;T	295,1,1;291;286	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	3252	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1725	234.4	0	.	p	.	0	I218M	NONSYN	652	654	ATA	1160	1162	ATG	274;274;273	A;T,C;G,T	274;273,1;272,1	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	3252	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1725	234.4	0	.	p	.	0	T256A	NONSYN	766	768	ACA	1274	1276	GCA	252;252;249	G;C;A	251;252;249	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	3252	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1725	234.4	0	.	p	.	0	W257T	NONSYN	769	771	TGG	1277	1279	ACG	246;246;246	A;C;G	246;246;246	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	3252	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1725	234.4	0	.	p	.	0	R258G	NONSYN	772	774	CGT	1280	1282	GGG	246;249;248	G,A;G,A;G,A	245,1;248,1;247,1	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	3252	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1725	234.4	0	.	p	.	0	A259V	NONSYN	775	777	GCT	1283	1285	GTT	245;243;243	G;T,A,G;T	245;240,1,1;242	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	3252	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1725	234.4	0	.	p	.	0	L279V	NONSYN	835	837	TTA	1343	1345	GTA	261;257;257	G,T;T;A	260,1;257;257	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	3252	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1725	234.4	0	.	p	.	0	S292T	NONSYN	874	876	TCT	1382	1384	ACT	257;255;251	A;C,T;T	257;254,1;251	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	3252	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1725	234.4	0	.	p	.	0	H294D	NONSYN	880	882	CAT	1388	1390	GAT	250;252;254	G;A;T	250;252;254	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	3252	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1725	234.4	0	.	p	.	0	Y298H	NONSYN	892	894	TAC	1400	1402	CAC	273;275;278	C;A,T;C	273;274,1;278	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	3252	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1725	234.4	1	SNP	p	G120K	1	.	.	358	360	AAG	865	867	CGG	241;241;242	C;G;G,T	241;241;241,1	porB1b.WHO_Z_02266c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	3252	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1725	234.4	1	SNP	p	D121N	0	.	.	361	363	GAC	868	871	CGC	241;235;235	C;G;C,A	241;235;234,1	porB1b.WHO_Z_02266c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	3252	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1725	234.4	1	SNP	p	A121D	1	.	.	361	363	GAC	868	871	CGC	241;235;235	C;G;C,A	241;235;234,1	porB1b.WHO_Z_02266c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	11568	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	5351	269.4	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2290	2292	AAT	316;316;317	A;A;T,G	316;316;314,3	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1658	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1574	131.0	1	SNP	p	V57M	1	.	.	169	171	ATG	828	830	ATG	305;306;305	A;T;G	305;306;305	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
